BRAF and melanoma: For instance, the failure of Vemurafenib treatment in colon cancer is related to a feedback activation of EGFR, which does not happen in melanoma cells because these exhibit a low expression of this receptor [8], although eventual EGFR activation may also happen in melanoma cells, conferring them resistance to BRAF inhibitors [9].